Banco Santander S.A. Sells 33,403 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Banco Santander S.A. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 47.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 37,732 shares of the biopharmaceutical company’s stock after selling 33,403 shares during the quarter. Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals were worth $29,124,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. WPG Advisers LLC boosted its position in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Entrust Financial LLC acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth $32,000. Caitlin John LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $34,000. Finally, MCF Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 0.1%

Shares of REGN stock opened at $612.14 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. The stock has a market cap of $64.72 billion, a P/E ratio of 14.92, a price-to-earnings-growth ratio of 1.34 and a beta of 0.25. The stock has a 50 day simple moving average of $692.11 and a 200 day simple moving average of $738.16. Regeneron Pharmaceuticals, Inc. has a 1 year low of $503.25 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same period in the previous year, the company posted $8.22 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

REGN has been the topic of a number of recent research reports. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Friday, March 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $800.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Finally, BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.